靶向雷帕霉素机制靶蛋白复合物2可减轻系统性红斑狼疮的免疫病理
研究探讨mTORC2在SLE发病中的作用及I型IFN信号对mTORC2的体内调控,并在IMQ诱导的T细胞特异性Rictor缺陷小鼠、IFNAR1缺陷Lpr小鼠、MRL/lpr小鼠及5例SLE患者PBMC体外T-B共培养中评估靶向mTORC2的疗效。结果显示Rictor-ASO改善MRL/lpr小鼠肾功能与病理,并在人PBMC共培养中显著减少免疫球蛋白和自身抗体产生(P < 0.05)。作者认为靶向mTORC2可能是SLE有前景的治疗策略。
要点
- T细胞特异性Rictor缺陷小鼠经IMQ处理后,年龄相关B细胞、浆细胞和生发中心B细胞减少,自身抗体产生少于WT小鼠。
- IFNAR1缺陷Lpr小鼠CD4+ T细胞mTORC2活性降低,伴CD4+ T细胞糖代谢恢复、T细胞迁移部分恢复及全身炎症减轻。
- Rictor-ASO改善MRL/lpr小鼠肾功能与病理及免疫病理;5例SLE患者PBMC的T-B共培养中RICTOR-ASO显著减少Ig和自身抗体产生(P < 0.05)。
核心结论
- 靶向mTORC2可能是SLE有前景的治疗策略。
研究设计与样本
- 在T细胞特异性Rictor(mTORC2关键组分)缺陷小鼠中局部应用咪喹莫特(IMQ)诱导狼疮样病并监测疾病发展。
- 在I型IFNAR缺陷Lpr小鼠中研究mTORC2信号和免疫表型变化。
- 在MRL/lpr狼疮小鼠模型中测试抗Rictor反义寡核苷酸(Rictor-ASO)的获益效应。
- 利用5例SLE患者PBMC来源的体外T-B共培养试验检测RICTOR-ASO的获益效应。
主要发现
- T细胞特异性Rictor缺陷小鼠经IMQ处理后,年龄相关B细胞、浆细胞和生发中心B细胞减少,自身抗体产生少于WT小鼠。
- IFNAR1缺陷Lpr小鼠CD4+ T细胞mTORC2活性降低,伴CD4+ T细胞糖代谢恢复、T细胞迁移部分恢复及全身炎症减轻。
- Rictor-ASO治疗改善MRL/lpr小鼠肾功能与病理,并改善免疫病理。
- 5例SLE患者PBMC来源的T-B共培养中,RICTOR-ASO显著减少免疫球蛋白(Ig)和自身抗体产生(P < 0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to explore the role of mechanistic target of rapamycin complex (mTORC) 2 in SLE development, and the in vivo regulation of mTORC2 by type I IFN signalling in autoimmunity, and to use mTORC2 targeting therapy to ameliorate lupus-like symptoms in an in vivo lupus mouse model and an in vitro co-culture model using human peripheral blood mononuclear cells (PBMCs). METHOD: We first induced lupus-like disease in T-cell-specific Rictor, a key component of mTORC2-deficient mice, by topical application of imiquimod (IMQ), and monitored disease development. Next, we investigated the changes in mTORC2 signalling and immunological phenotypes in type I IFNAR-deficient Lpr mice. We then tested the beneficial effects of anti-Rictor antisense oligonucleotide (Rictor-ASO) in a mouse model of lupus: MRL/lpr mice. Finally, we examined the beneficial effects of RICTOR-ASO on SLE patients' PBMCs using an in vitro T-B co-culture assay. RESULTS: T-cell-specific Rictor-deficient mice have reduced age-associated B cells, plasma cells and germinal centre B cells, and less autoantibody production than WT mice, following IMQ treatment. IFNAR1-deficient Lpr mice have reduced mTORC2 activity in CD4+ T cells, accompanied by restored CD4+ T cell glucose metabolism, partially recovered T cell trafficking, and reduced systemic inflammation. Rictor-ASO treatment improved renal function and pathology in MRL/lpr mice, and improved immunopathology. In a human SLE (N = 5) PBMCs derived T-B co-culture assay, RICTOR-ASO significantly reduced the production of immunoglobulin (Ig) and autoantibodies (P < 0.05). CONCLUSION: Targeting mTORC2 could be a promising therapeutic strategy for SLE.
引用
- Ai M, Zhou X, Carrer M, et al. Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in systemic lupus erythematosus. Rheumatology (Oxford). 2025. PMID: 39656824. doi:10.1093/rheumatology/keae662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。